RCS - Moderna Inc - Moderna Showcases Research at ESCMID 2025

ModernaAnnouncement

07/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250407:nRSG8192Da&default-theme=true

RNS Number : 8192D  Moderna Inc  07 April 2025

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / April 7,
2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will
present research across multiple infectious disease areas, including COVID-19,
influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV),
norovirus, and mpox, at the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April
11-15, 2025.

Moderna will present twelve scientific presentations at the ESCMID 2025
Global Congress, including three oral presentations, one e-poster
presentation, and eight poster presentations, highlighting the breadth of its
research in respiratory and emerging infectious diseases.

COVID-19

·      Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines
against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation

Presenter: Frances Priddy

Session: Advances in vaccine effectiveness for viral respiratory infections

Date: April 12 | Time & Location: 11:00 (Hall 9)

·      Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding
and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses -
Oral Presentation

Presenter: Spyros Chalkias

Session: Vaccines and prophylaxis against respiratory viral infections

Date: April 13 | Time & Location: 11:00 (Hall 9)

·      Clinical evaluation of a SARS-CoV-2 spike receptor-binding and
N-terminal domain COVID-19 vaccine - Poster Presentation

Presenter: Spyros Chalkias

Session: COVID-19

Date: April 12 | Time & Location: 12:00 (Poster Hall)

·      Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and
receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants
aged ≥12 years - Poster Presentation

Presenter: Christina Grassi

Session: COVID-19

Date: April 12 | Time & Location: 12:00 (Poster Hall)

RSV

·      Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged
≥60 Years - E-Poster Presentation

Presenter: Mihir Desai

Session: On the frontiers of vaccine-driven prevention

Date: April 12 | Time & Location: 08:30 (Arena 1)

·      Safety and immunogenicity of mRNA-1345 revaccination at 24 months
in adults ≥60 years - Poster Presentation

Presenter: Mihir Desai

Session: Clinical Trials

Date: April 15 | Time & Location: 12:00 (Poster Hall)

·      Burden of chronic medical conditions that are risk factors for
severe RSV among adults aged 18-59 years in the United States - Poster
Presentation

Presenter: Clarisse Demont

Session: Influenza and respiratory viruses

Date: April 12 | Time & Location: 12:00 (Poster Hall)

·      Association of virology swab positivity in adults aged ≥40
years with Computerized Medical Record Reported Acute Respiratory Infection
(ARI) Subgroups: Observational Study of ARI (ObservatARI) - Poster
Presentation

Presenter: Simon De Lusignan

Session: Influenza and respiratory viruses

Date: April 12 | Time & Location: 12:00 (Poster Hall)

Mpox

·      Safety and immunogenicity of mRNA mpox vaccine candidate
mRNA-1769: Interim analysis results from a Phase 1/2 Trial - Oral
Presentation

Presenter: Hiwot Hiruy

Session: Novel vaccines in clinical development

Date: April 14 | Time & Location: 17:30 (Hall 3)

Cytomegalovirus

·      Long-term safety and immunogenicity of cytomegalovirus mRNA-1647
vaccine in healthy adults: 36-month results from a phase 2 extension trial -
Poster Presentation

Presenter: Ben Lorenz

Session: Clinical Trials

Date: April 15 | Time & Location: 12:00 (Poster Hall)

Influenza

·      Six-month persistence and safety of mRNA-based influenza or
multicomponent influenza/COVID-19 vaccines versus licensed comparators in
adults aged ≥18 years - Poster Presentation

Presenter: Mieke Soens

Session: Influenza and respiratory viruses

Date: April 12 | Time & Location: 12:00 (Poster Hall)

Norovirus

·      Incidence and severity of sporadic, medically attended norovirus
infection in the United States, 2023-2024 - Poster Presentation

Presenter: Mark A. Schmidt

Session: Viral epidemiology - general, prevalence studies, molecular and
genomic epidemiology

Date: April 12 | Time & Location: 12:00 (Poster Hall)

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the
advancement of mRNA technology, Moderna is reimagining how medicines are made
and transforming how we treat and prevent disease for everyone. By working at
the intersection of science, technology and health for more than a decade, the
company has developed medicines at unprecedented speed and efficiency,
including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases and
autoimmune diseases. With a unique culture and a global team driven by the
Moderna values and mindsets to responsibly change the future of human health,
Moderna strives to deliver the greatest possible impact to people through mRNA
medicines. For more information about Moderna, please visit modernatx.com
(https://pr.report/1ume) and connect with us on X (formerly Twitter),
Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended, including
statements regarding: the potential for Moderna's vaccine candidates to
alleviate disease outcomes. The forward-looking statements in this press
release are neither promises nor guarantees, and you should not place undue
reliance on these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are beyond
Moderna's control and which could cause actual results to differ materially
from those expressed or implied by these forward-looking statements. These
risks, uncertainties, and other factors include, among others, those risks and
uncertainties described under the heading "Risk Factors" in Moderna's Annual
Report on Form 10-K for the fiscal year ended December 31, 2024, and in
subsequent filings made by Moderna with the U.S. Securities and Exchange
Commission, which are available on the SEC's website at www.sec.gov
(https://pr.report/XLhRyDNS) . Except as required by law, Moderna disclaims
any intention or responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new information,
future developments or otherwise. These forward-looking statements are based
on Moderna's current expectations and speak only as of the date of this press
release.

Moderna Contacts

Media:

Luke Mircea-Willats

Senior Director, International Communications

Luke.Mirceawillats@modernatx.com

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

+1 617-209-5834

Lavina.Talukdar@modernatx.com

SOURCE: Moderna Inc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKABPBBKDNQK